Roche Pharmaceutical Asia Pacific Operation Center settled in China
Release time: 2010-01-21 & nbsp & nbsp & nbsp Source:
As the first and only multinational pharmaceutical enterprise with its own full -functional area headquarters in China，Roche Pharmaceutical announced: It will start in the first quarter of 2010，List the Chinese area as one of the Roche's global core team，and the United States、Germany and other six developed countries market side by side。This is the president of Roche Pharmaceutical Asia Pacific Mr. Lu Ke's latest strategic deployment disclosed at the "Roche Asia -Pacific Operation Center and China Strategic Report" held in Shanghai on January 13, 2010。Deputy Mayor of Shanghai Shen Xiaoming Mr. Director of the Medical Service Supervision Department of the Ministry of Health Mr. Zhou Jun, Roche President Asia Pacific President Mr. Lu Ke, General Manager of Shanghai Roche Pharmaceutical Co., Ltd. Mr. Zhou Pingshan attended the meeting and delivered a speech.
Behind the "third" of the two worlds
September 2009，Roche Pharmaceutical Asia Pacific Operation Center officially settled in Shanghai, China。This is the regional headquarters in the full sense: strategy、Finance、Personnel、Information、The operation departments of the Ministry of Medicine all settled in Zhangjiang。Before，The Asia -Pacific Drug Cooperation Department was established in Shanghai in 2008，2009，Roche's Drug Development China Center Stake Sports Bettingis also promoted to Asia Pacific Center。
Current，Most multinational enterprises just classify China to developing countries market，or a member of the Asia Pacific market。And Roche first set the Asia -Pacific "Command" in China，and "Elite Forces"。This， Mr. Lu Ke said at the meeting，"Shanghai meets the core appeal of an international pharmaceutical company to the location of the regional headquarters，At the same time, it is also expected to become an innovative base for biotechnology and drug development research。Roche China will become a more powerful growth engine in the world in Roche。”
It is reported，Roche made a judgment as early as the early 21st century，Asia Pacific will be the fastest growing market，Among them, China's contribution rate is the largest。Existing prediction indicates，The Chinese market will become the third largest pharmaceutical market in the world in 2011，Roche Pharmaceutical Internal Forecast: China will become the world's third largest market in the world in 2013。Considering that Roche itself focuses on innovative drugs and has a strong research or approved drug product line，This prediction undoubtedly shows: Roche believes，With the further improvement of Chinese medical reform and people's livelihood welfare，Fighting oncology drugs、The demand for the prescription drug market of drugs and hepatitis antiviral drugs after organ transplantation will increase rapidly。
Mr. Lu Ke said: "Although China's contribution rate in Roche is not very large at present，But considering the annual growth rate of high -speed growth in the Asia -Pacific region，and China attach importance to medical level and benefits，This "frog jump" in the Chinese market will definitely happen! "
Select Liangmu and inhabit
The pharmaceutical industry has always been a "big household" to absorb high -end talents, And Roche's "appetite" of a full -featured regional headquarters and the value chain function under its jurisdiction is more considerable: except for the initial molecular screening and development of new compounds，Also needs to be good at model design、"translation My stake betting apptalents" of clinical research and mathematical statistics; drug registration experts who need to be proficient in Chinese regulations and policies，Short the time from the results of clinical research to the time of drug review; need to be highly sensitive to the market demand and trend of the local market epidemiological market, the market strategy consultant，Provide analysis，Help decision; and finance、Personnel、Top talents in various fields such as logistics to ensure the efficient rotation of the entire Asia Pacific engine。and Shanghai，Have more than 60 universities、60 million college students and more than 200,000 graduate students。China has the strength to keep to foreign pharmaceutical companies，Especially the transnational corporate headquarters transport first -class talents。 Mr. Lu Ke said，The first priority to go to China is to recruit people: "We want to recruit the best talents in China，Because we want to be the best pharmaceutical company，The best employer。”
In addition，Shanghai's headquarters economic environment is also a climate。2002，Shanghai issued the "Interim Provisions on Encouraging Foreign Corporations to Establish Regional Headquarters"，and formulated a series of preferential policies with quite attractiveness; Jiangsu, Zhejiang and East China, near Shanghai、Many provinces and cities in China，Now it has become the manufacturing base of multinational companies。A large number of factories spread throughout it，This strong industrial foundation has become a necessary condition for the establishment of a "headquarters economy" in Shanghai in Shanghai。
It is reported，It is expected to be in 2010，Foreign -funded enterprise headquarters in Huanying Camp will be expected to reach 610，Among them, foreign -funded brain -type R & D centers will reach 254。Facing the new situation in the international and domestic situation，Shanghai headquarters economy still has a lot of development space。Roche decisively decided to settle in Shanghai during the booming period of Shanghai，It is also full recognition of its future。
stake betting appThe finishing touch upgrade "Value Chain"
It is understood，Roche Pharmaceutical will settle in China for this time the Asia -Pacific Operation Center，On the one hand, we value the huge potential of the Chinese market and the excellent environment of Shanghai。On the other hand，Roche has improved the third complete medical value chain worldwide in Shanghai and Europe in Shanghai, China。
At the end of 2004，Roche R & D (China) Co., Ltd.，It is the first time that Roche Group has set up an independent research and development center in the development market。
2007，Roche set up Roche Pharmaceutical Development China Center in China，It is the first pharmaceutical development center in China and even the Asia -Pacific region to have all functions required for clinical development.。Mr. Zhou Pingshan, general manager of Shanghai Roche Pharmaceutical Co., Ltd., emphasized at a strategic report meeting: past，The core ability of drug development is mainly concentrated in Europe and the United States; the R & D centers of Chinese multinational pharmaceutical companies are also concentrated in drug research，Just looking for new compounds as nodes。Only Roche's drug development has extended from 2007 to a drug design、Clinical Studies、The complete drug development process of applying for the new drug as the end。From this，Roche has built a complete medical value chain from molecular compound to drug listing in China。For China，This means that Roche's full set of pharmaceutical knowledge and experience can be realized in local conversion，This major knowledge output and localization decision，Is Roche's major investment in Chinese pharmaceutical innovation capabilities and potential。
Behind the big pen is confidence。As an enterprise with innovation as the main driving force，Roche is full of confidence in the innovation potential of himself and Shanghai。It is expected to be in 2014，Six of the top 10 drugs in the world's sales are biological innovation medicines，4 of which are tumor drugs，There is Roche's Hedine、Avastin (Avastin) and Merohua。In drug development，Roche has more than 150 stake betting appinnovative partners worldwide，and Fudan University，Shanghai Jiaotong University and other well -known universities maintain a good collaborative relationship。For example, Dafi, who is famous during the flu，Both are derived from the cooperation between Roche and other innovative companies。Shanghai side，It is expected to be from 2012，The city's total economic economy in the biomedical industry will reach 200 billion yuan，and initially built the innovative product manufacturing center of domestic biomedicine、Business Center and R & D Center。Innovation of biopharmaceuticals becomes the future that Roche and Shanghai pay attention to。At the report meeting，Government officials and Roche high -level discussions on future cooperation matters。
"Shanghai has such a plan，Roche has such a layout "，Roche President Asia Pacific President Mr. Lu Ke said，"Select Shanghai as the location of the Asia -Pacific operation center，Just stand in the future and look at the present。”
Behind the "third" of the two worlds
September 2009，Roche Pharmaceutical Asia Pacific Operation Center officially settled in Shanghai, China。This is the regional headquarters in the full sense: strategy、Finance、Personnel、Information、The operation departments of the Ministry of Medicine all settled in Zhangjiang。Before，The Asia -Pacific Drug Cooperation Department was established in Shanghai in 2008，2009，Roche's Drug Development China Center Stake Sports Bettingis also promoted to Asia Pacific Center。
Current，Most multinational enterprises just classify China to developing countries market，or a member of the Asia Pacific market。And Roche first set the Asia -Pacific "Command" in China，and "Elite Forces"。This， Mr. Lu Ke said at the meeting，"Shanghai meets the core appeal of an international pharmaceutical company to the location of the regional headquarters，At the same time, it is also expected to become an innovative base for biotechnology and drug development research。Roche China will become a more powerful growth engine in the world in Roche。”
It is reported，Roche made a judgment as early as the early 21st century，Asia Pacific will be the fastest growing market，Among them, China's contribution rate is the largest。Existing prediction indicates，The Chinese market will become the third largest pharmaceutical market in the world in 2011，Roche Pharmaceutical Internal Forecast: China will become the world's third largest market in the world in 2013。Considering that Roche itself focuses on innovative drugs and has a strong research or approved drug product line，This prediction undoubtedly shows: Roche believes，With the further improvement of Chinese medical reform and people's livelihood welfare，Fighting oncology drugs、The demand for the prescription drug market of drugs and hepatitis antiviral drugs after organ transplantation will increase rapidly。
Mr. Lu Ke said: "Although China's contribution rate in Roche is not very large at present，But considering the annual growth rate of high -speed growth in the Asia -Pacific region，and China attach importance to medical level and benefits，This "frog jump" in the Chinese market will definitely happen! "
Select Liangmu and inhabit
The pharmaceutical industry has always been a "big household" to absorb high -end talents, And Roche's "appetite" of a full -featured regional headquarters and the value chain function under its jurisdiction is more considerable: except for the initial molecular screening and development of new compounds，Also needs to be good at model design、"translation My stake betting apptalents" of clinical research and mathematical statistics; drug registration experts who need to be proficient in Chinese regulations and policies，Short the time from the results of clinical research to the time of drug review; need to be highly sensitive to the market demand and trend of the local market epidemiological market, the market strategy consultant，Provide analysis，Help decision; and finance、Personnel、Top talents in various fields such as logistics to ensure the efficient rotation of the entire Asia Pacific engine。and Shanghai，Have more than 60 universities、60 million college students and more than 200,000 graduate students。China has the strength to keep to foreign pharmaceutical companies，Especially the transnational corporate headquarters transport first -class talents。 Mr. Lu Ke said，The first priority to go to China is to recruit people: "We want to recruit the best talents in China，Because we want to be the best pharmaceutical company，The best employer。”
In addition，Shanghai's headquarters economic environment is also a climate。2002，Shanghai issued the "Interim Provisions on Encouraging Foreign Corporations to Establish Regional Headquarters"，and formulated a series of preferential policies with quite attractiveness; Jiangsu, Zhejiang and East China, near Shanghai、Many provinces and cities in China，Now it has become the manufacturing base of multinational companies。A large number of factories spread throughout it，This strong industrial foundation has become a necessary condition for the establishment of a "headquarters economy" in Shanghai in Shanghai。
It is reported，It is expected to be in 2010，Foreign -funded enterprise headquarters in Huanying Camp will be expected to reach 610，Among them, foreign -funded brain -type R & D centers will reach 254。Facing the new situation in the international and domestic situation，Shanghai headquarters economy still has a lot of development space。Roche decisively decided to settle in Shanghai during the booming period of Shanghai，It is also full recognition of its future。
stake betting appThe finishing touch upgrade "Value Chain"
It is understood，Roche Pharmaceutical will settle in China for this time the Asia -Pacific Operation Center，On the one hand, we value the huge potential of the Chinese market and the excellent environment of Shanghai。On the other hand，Roche has improved the third complete medical value chain worldwide in Shanghai and Europe in Shanghai, China。
At the end of 2004，Roche R & D (China) Co., Ltd.，It is the first time that Roche Group has set up an independent research and development center in the development market。
2007，Roche set up Roche Pharmaceutical Development China Center in China，It is the first pharmaceutical development center in China and even the Asia -Pacific region to have all functions required for clinical development.。Mr. Zhou Pingshan, general manager of Shanghai Roche Pharmaceutical Co., Ltd., emphasized at a strategic report meeting: past，The core ability of drug development is mainly concentrated in Europe and the United States; the R & D centers of Chinese multinational pharmaceutical companies are also concentrated in drug research，Just looking for new compounds as nodes。Only Roche's drug development has extended from 2007 to a drug design、Clinical Studies、The complete drug development process of applying for the new drug as the end。From this，Roche has built a complete medical value chain from molecular compound to drug listing in China。For China，This means that Roche's full set of pharmaceutical knowledge and experience can be realized in local conversion，This major knowledge output and localization decision，Is Roche's major investment in Chinese pharmaceutical innovation capabilities and potential。
Behind the big pen is confidence。As an enterprise with innovation as the main driving force，Roche is full of confidence in the innovation potential of himself and Shanghai。It is expected to be in 2014，Six of the top 10 drugs in the world's sales are biological innovation medicines，4 of which are tumor drugs，There is Roche's Hedine、Avastin (Avastin) and Merohua。In drug development，Roche has more than 150 stake betting appinnovative partners worldwide，and Fudan University，Shanghai Jiaotong University and other well -known universities maintain a good collaborative relationship。For example, Dafi, who is famous during the flu，Both are derived from the cooperation between Roche and other innovative companies。Shanghai side，It is expected to be from 2012，The city's total economic economy in the biomedical industry will reach 200 billion yuan，and initially built the innovative product manufacturing center of domestic biomedicine、Business Center and R & D Center。Innovation of biopharmaceuticals becomes the future that Roche and Shanghai pay attention to。At the report meeting，Government officials and Roche high -level discussions on future cooperation matters。
"Shanghai has such a plan，Roche has such a layout "，Roche President Asia Pacific President Mr. Lu Ke said，"Select Shanghai as the location of the Asia -Pacific operation center，Just stand in the future and look at the present。”
